Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment ; day:3 ; month:10 ; year:2023 ; pages:1-9
Clinical rheumatology ; (3.10.2023), 1-9
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Mease, Philip J.
Gottlieb, Alice B.
Ogdie, Alexis
McInnes, Iain B.
Chakravarty, Soumya D.
Rampakakis, Emmanouil
Kollmeier, Alexa
Xu, Xie L.
Shawi, May
Lavie, Frederic
Kishimoto, Mitsumasa
Rahman, Proton
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-023-06745-y
- URN
-
urn:nbn:de:101:1-2023122421025983032232
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mease, Philip J.
- Gottlieb, Alice B.
- Ogdie, Alexis
- McInnes, Iain B.
- Chakravarty, Soumya D.
- Rampakakis, Emmanouil
- Kollmeier, Alexa
- Xu, Xie L.
- Shawi, May
- Lavie, Frederic
- Kishimoto, Mitsumasa
- Rahman, Proton
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Clinical and radiographic evaluation of the Periodontium with biologic width invasion
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Clinical and radiographic evaluation of the Periodontium with biologic width invasion
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Clinical and radiographic evaluation of the Periodontium with biologic width invasion
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis